CalciMedica, Inc. (CALC)

CalciMedica announced a collaboration with Telperian to integrate an artificial intelligence engine into the analysis of clinical trial datasets for Auxora. CalciMedica reported its third-quarter 2025 financial results and provided clinical and corporate updates. The company announced the publication of preclinical data in JCI Insight supporting CRAC channel inhibitors as a potential therapy for pulmonary arterial hypertension and presented data from a preclinical study of Auxora in an animal model of AKI at ASN Kidney Week 2025. CalciMedica announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The company also reported its first-quarter 2025 financial results and provided clinical and corporate updates, highlighting ongoing enrollment in its Phase 2 KOURAGE trial for AKI with associated AHRF, with data expected around the end of 2025. CalciMedica reported its 2024 financial results and provided clinical and corporate updates, stating that its cash position, combined with recent debt financing, was expected to fund operations into mid-2026. The company secured a credit facility for up to $32.5 million to support the continued development of its product pipeline. As of November 6, 2025, CalciMedica's stock price was $3.06, with a market capitalization of $44.1 million.

Information regarding demand seasonality for CalciMedica, Inc.'s products and services is not available in the provided search results. As a clinical-stage biopharmaceutical company, its primary focus is on the development and clinical testing of its drug candidates, rather than the commercial sale of products, which typically drives demand seasonality.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. The company is developing Auxora for the treatment of various conditions, including acute pancreatitis, asparaginase-induced pancreatic toxicity, acute kidney injury, severe COVID-19 pneumonia, acute ulcerative colitis, traumatic brain injury, and allergic asthma. CalciMedica is also exploring oral CRAC channel inhibitors for chronic inflammatory indications.

CalciMedica, Inc. is headquartered in La Jolla, California, United States. Specific details about its broader geographic operational footprint beyond its headquarters are not explicitly provided.

Information specifically detailing CalciMedica, Inc.'s brand reputation in the past year is not available in the provided search results. However, the company regularly issues press releases regarding its clinical trial progress, financial results, and participation in industry conferences, which contribute to its public image within the biopharmaceutical community.

Specific details regarding major institutional and individual owners of CalciMedica, Inc. are not available in the provided search results.